AIM4ALL is already working with Pharmaceutical Manufacturers in the UK Health System.

These engagements, initiated early in the product lifecycle, are focused on complementing traditional clinical trial evidence with high quality, structured, governance-compliant, real-world data, collected from therapy-eligible patients before and after product launch.

This work includes:

-          Agreeing clinical datasets and HTA-relevant data elements,

-          Standardising care pathways,

-          Digitalising data collection processes,

-          Providing pseudonymised insights, and

-          In collaboration with Remedium Capital, working towards more acceptable MFN net launch pricing.